ID   IGROV-1/MX3
AC   CVCL_EQ59
SY   IGROV1/MX3; Igrov1 MX3; MX3
DR   cancercelllines; CVCL_EQ59
DR   Wikidata; Q54897386
RX   PubMed=10493507;
RX   PubMed=10825126;
RX   PubMed=11309308;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone.
CC   Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Lys654Serfs*47 (c.1961delA); ClinVar=VCV000037438; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys1108Argfs*11 (c.3323delA) (p.Gln1107fs) (c.3320delA); ClinVar=VCV000225716; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg38Cys (c.112C>T); ClinVar=VCV000376493; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ter1069TrpinsLysAspAsn (c.3207A>G); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gly231Alafs*10 (c.692delG); ClinVar=VCV001756201; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu495Pro (c.1484T>C); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Leufs*59 (c.267dupC) (c.267_268insC); ClinVar=VCV000634762; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1304 ! IGROV-1
SX   Female
AG   47Y
CA   Cancer cell line
DT   Created: 26-09-16; Last updated: 05-10-23; Version: 16
//
RX   PubMed=10493507;
RA   Maliepaard M., van Gastelen M.A., de Jong L.A., Pluim D.,
RA   van Waardenburg R.C.A.M., Ruevekamp-Helmers M.C., Floot B.G.J.,
RA   Schellens J.H.M.;
RT   "Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected
RT   ovarian tumor cell line.";
RL   Cancer Res. 59:4559-4563(1999).
//
RX   PubMed=10825126;
RA   Scheffer G.L., Maliepaard M., Pijnenborg A.C.L.M., van Gastelen M.A.,
RA   de Jong M.C., Schroeijers A.B., van der Kolk D.M., Allen J.D.,
RA   Ross D.D., van der Valk P., Dalton W.S., Schellens J.H.M.,
RA   Scheper R.J.;
RT   "Breast cancer resistance protein is localized at the plasma membrane
RT   in mitoxantrone- and topotecan-resistant cell lines.";
RL   Cancer Res. 60:2589-2593(2000).
//
RX   PubMed=11309308;
RA   Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A.,
RA   Pijnenborg A.C.L.M., Schinkel A.H., van de Vijver M.J., Scheper R.J.,
RA   Schellens J.H.M.;
RT   "Subcellular localization and distribution of the breast cancer
RT   resistance protein transporter in normal human tissues.";
RL   Cancer Res. 61:3458-3464(2001).
//